Profile data is unavailable for this security.
About the company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
- Revenue in CHF (TTM)42.54bn
- Net income in CHF7.81bn
- Incorporated1996
- Employees76.06k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
More ▼
Mergers & acquisitions
| Acquired company | NOVN:SWX since announced | Transaction value |
|---|---|---|
| IFM Due Inc | 2.92% | 835.00m |
| Cytokinetics Inc | -0.29% | -- |
| Calypso Biotech BV | -0.29% | 425.00m |
| SanReno Therapeutics | 0.35% | -- |
| DTx Pharma Inc | 6.11% | 500.00m |
Data delayed at least 15 minutes, as of Apr 24 2024 13:48 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 6.72bn | 654.00m | 39.20bn | 18.00k | 59.37 | 4.02 | 31.90 | 5.84 | 8.87 | 8.87 | 91.16 | 131.07 | 0.3928 | 2.80 | 5.84 | 373,166.70 | 3.83 | 5.07 | 4.64 | 6.21 | 29.00 | 39.15 | 9.75 | 14.52 | 1.20 | 11.86 | 0.2275 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
| Merck KGaA | 20.49bn | 2.76bn | 65.19bn | 62.91k | 23.65 | 2.50 | 14.48 | 3.18 | 6.50 | 6.50 | 48.27 | 61.36 | 0.4327 | 1.86 | 5.03 | 333,709.50 | 5.84 | 5.64 | 7.20 | 7.27 | 59.03 | 61.86 | 13.49 | 12.97 | 0.8916 | 32.81 | 0.2694 | 9.26 | -5.57 | 7.19 | -15.09 | 21.40 | 14.77 | 11.97 |
| GSK plc | 34.43bn | 5.59bn | 77.69bn | 70.21k | 13.73 | 5.02 | 8.39 | 2.26 | 1.20 | 1.20 | 7.39 | 3.29 | 0.5091 | 1.57 | 4.20 | 431,949.00 | 8.91 | 6.74 | 13.91 | 10.71 | 72.42 | 70.29 | 17.50 | 16.93 | 0.624 | 10.99 | 0.5848 | 79.55 | 3.42 | -0.322 | 15.79 | 7.10 | 5.47 | -10.32 |
| Sanofi SA | 45.32bn | 5.27bn | 109.67bn | 87.99k | 20.66 | 1.50 | 14.55 | 2.42 | 4.30 | 4.30 | 37.04 | 59.17 | 0.3669 | 1.53 | 5.51 | 527,808.70 | 4.38 | 5.87 | 5.43 | 7.16 | 69.35 | 68.78 | 11.95 | 16.90 | 0.8675 | 66.19 | 0.1986 | 60.51 | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | 4.14 |
| Roche Holding AG | 58.72bn | 11.50bn | 188.07bn | 103.61k | 16.06 | 6.25 | 11.89 | 3.20 | 14.30 | 14.30 | 73.03 | 36.77 | 0.6574 | 1.91 | 5.19 | 566,729.40 | 13.84 | 16.12 | 20.84 | 25.24 | 73.39 | 71.48 | 21.05 | 22.98 | 1.04 | 20.77 | 0.4676 | 58.80 | -7.21 | 0.6494 | -7.43 | 1.90 | 10.01 | 1.99 |
| Novartis AG | 42.54bn | 7.81bn | 194.75bn | 76.06k | 23.69 | 4.27 | 12.50 | 4.58 | 3.75 | 6.52 | 20.36 | 20.81 | 0.4293 | 1.84 | 6.15 | 559,316.30 | 7.89 | 8.53 | 10.57 | 11.23 | 74.24 | 72.93 | 18.37 | 22.68 | 0.931 | 13.16 | 0.3605 | 67.20 | 7.57 | 0.2779 | 41.64 | -7.71 | 0.7808 | 6.19 |
| AstraZeneca plc | 41.78bn | 5.43bn | 196.74bn | 89.90k | 36.48 | 5.51 | 19.01 | 4.71 | 3.06 | 3.06 | 23.56 | 20.29 | 0.4637 | 1.59 | 4.05 | 409,363.80 | 6.03 | 3.34 | 8.47 | 4.61 | 82.39 | 79.64 | 13.01 | 7.69 | 0.6427 | 6.34 | 0.4222 | 143.06 | 3.29 | 15.71 | 81.11 | 22.54 | 22.47 | 1.10 |
| Novo Nordisk A/S | 30.38bn | 10.95bn | 400.53bn | 63.37k | 47.86 | 37.29 | 33.66 | 13.18 | 18.62 | 18.62 | 51.68 | 23.90 | 0.8359 | 1.27 | 4.03 | 3,665,157.00 | 30.12 | 29.17 | 63.12 | 58.62 | 84.60 | 83.93 | 36.03 | 33.55 | 0.6356 | -- | 0.2022 | 50.13 | 31.26 | 15.74 | 50.71 | 16.72 | 25.67 | 18.20 |
Data as of Apr 24 2024. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF
17.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 77.36m | 3.53% |
| UBS Asset Management Switzerland AGas of 05 Mar 2024 | 68.39m | 3.12% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 55.32m | 2.53% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 38.20m | 1.74% |
| Wellington Management Co. LLPas of 04 Apr 2024 | 36.75m | 1.68% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Mar 2024 | 31.31m | 1.43% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 26.97m | 1.23% |
| Artisan Partners LPas of 31 Dec 2023 | 18.84m | 0.86% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 17.55m | 0.80% |
| Dodge & Coxas of 31 Dec 2023 | 15.53m | 0.71% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
